Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Surgery for this rare cancer required the removal of Walther’s left eye. “This is my journey,” she said, “and I have to travel it.”
More than 40% of patients treated with the bispecific T-cell engager experienced complete remission.
Newly FDA-approved drugs for ovarian, bladder, liver cancer, and more.
Mosunetuzumab is the first bispecific antibody, a type of immunotherapy, approved to treat non-Hodgkin lymphoma.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.
Umbralisib led to remission in 49% of patients with marginal zone lymphoma and 43% of those with follicular lymphoma.
A study showed a 69% response rate for patients whose cancer carries the targeted mutation.
Approval was based on the results of two clinical trials: AUGMENT and MAGNIFY.
The overall response rate was 50%, with a complete response rate of 32%.
The custom immunotherapy is now indicated for adults with relapsed or refractory lymphoma.
Findings from the JULIET trial support expanded Food and Drug Administration approval of customized T cells.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.